CHARLES D. BAKER
Governor

KARYN E. POLITO
Lieutenant Governor

MARYLOU SUDDERS
Secretary

DANIEL TSAI
Assistant Secretary for
MassHealth

www.mass.gov/eohhs

Administrative Bulletin 16-07

101 CMR 320: Clinical Laboratory Services

Effective January 1, 2016

CPT/HCPCS 2016 Procedure Code Update

Under the authority of regulation 101 CMR 320.01(3): *Coding Updates and Corrections*, the Executive Office of Health and Human Services is adding new procedure codes and deleting outdated codes. The rates for code additions are priced at 74.67% of the prevailing Medicare fee if available. The CPT/HCPCS changes, effective January 1, 2016, are as follows:

Code	Change	Rate	Code Description (if applicable)
80081	Addition	$76.14	Obstetric panel (includes HIV testing)
81162	Addition	$1856.19	BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis
81170	Addition	$246.05	ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) (eg, acquired imatinib tyrosine kinase inhibitor resistance), gene analysis, variants in the kinase domain
81218	Addition	$246.05	CEBPA (CCAAT/enhancer binding protein [C/EBP], alpha) (eg, acute myeloid leukemia), gene analysis, full gene sequence
81219	Addition	$123.71	CALR (calreticulin) (eg, myeloproliferative disorders), gene analysis, common variants in exon 9
81272	Addition	$246.05	KIT (v-kit hardy Zukerman 4 feline sarcoma viral oncogene homolog) (eg, gastrointestinal stromal tumor [GIST], acute myeloid leukemia, melanoma), gene analysis, targeted sequence analysis (eg, exons 8, 11, 13, 17, 18)
81273	Addition	$93.24	KIT (v-kit hardy Zukerman 4 feline sarcoma viral oncogene homolog) (eg mastocytosis), gene analysis, D816 variant(s)
81276	Addition	$147.24	KRAS (Kristen rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)
81311	Addition	$220.87	NRAS (neuroblastoma RAS viral [v-ras] oncogene homolog (eg, colorectal carcinoma), gene analysis, variants in exon 2 (eg, codons 12 and 13) and exon 3 (eg, codon 61)
81314	Addition	$246.05	PDGFRA (platelet-derived growth factor receptor, alpha polypeptide) (gastrointestinal stromal tumor [GIST]), gene analysis, targeted sequence analysis (eg, exons 12, 18)

Code	Change	Rate	Code Description (if applicable)
81412	Addition	I.C.	Ashkenazi Jewish associated disorders (eg, Bloom syndrome, Canavan disease, cystic fibrosis, familial dysautonomia, Fanconi anemia group C, Gaucher disease, Tay-Sachs disease), genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1 and SMPD1
81432	Addition	I.C.	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 14 genes, including ATM, BRCA1, BRCA2, BRIP1, CDH1, MLH1, MSH2, MSH6, NBN, PALB2, PTEN, RAD51C, STK11, and TP53
81433	Addition	I.C.	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); duplication/deletion analysis panel, must include analysis for BRCA1, BRCA2, MLH1, MSH2, and STK11
81434	Addition	I.C.	Hereditary retinal disorders (eg, pigmentosa, Leber congenital amaurosis, cone-rod dystrophy), genomic sequence analysis panel, must include sequencing of at least 15 genes, including ABCA4, CNGA1, CRB1, EYS, PDE6A, PDE6B, PRPF31, PRPH2, RDH12, RH0, RP1, RP2, RPE65, RPGR, and USH2A
81437	Addition	I.C.	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); genomic sequence analysis panel, must include sequencing of at least 6 genes, including MAX, SDHB, SDHC, SDHD, TMEM127 and VHL
81438	Addition	I.C.	Hereditary neuroendocrine tumor disorders (eg, medullary thyroid carcinoma, parathyroid carcinoma, malignant pheochromocytoma or paraganglioma); duplication/deletion analysis panel, must include analyses for SDHB, SDHC, SDHD, and VHL
81442	Addition	I.C.	Noonan spectrum disorders (eg, Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome, leopard syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1
81490	Addition	I.C.	Autoimmune (rheumatoid arthritis) analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score
81493	Addition	I.C.	Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score
81525	Addition	I.C.	Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping) utilizing formalion-fixed paraffin-embedded tissue, algorithm reported as a positive or negative result
81528	Addition	$373.19	Oncology (colorectal cancer) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result

Code	Change	Rate	Code Description (if applicable)
81535	Addition	$432.68	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination
81536	Addition	$132.58	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure)
81538	Addition	I.C.	Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival
81540	Addition	I.C.	Oncology (tumor of unknown origin) mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin – fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype
81545	Addition	I.C.	Oncology (thyroid), gene expression analysis of 142 genes, utilizing fine needle aspirate, algorithm reported as a categorical result (eg, benign or suspicious)
81595	Addition	I.C.	Cardiology (heart transplant), mRNA, gene expression profiling by real-time quantitative (PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score
82486	Delete		
82487	Delete		
82488	Delete		
82489	Delete		
82491	Delete		
82492	Delete		
82541	Delete		
82543	Delete		
82544	Delete		
83788	Delete		
G0431	Delete		
G0434	Delete		
G0477	Addition	$8.92	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g., immunoassay) capable of being read by direct optical observation only (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service
G0478	Addition	$11.89	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g., immunoassay) read by instrument-assisted direct optical observation only (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service
G0479	Addition	$47.55	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures by instrument chemistry analyzers utilizing immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when performed, per date of service

Code	Change	Rate	Code Description (if applicable)
G0480	Addition	$59.69	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)); qualitative or quantitative, all sources, includes specimen validity testing, per day, 1-7 drug class(es), including metabolite(s) if performed
G0481	Addition	$91.84	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)); qualitative or quantitative, all sources, includes specimen validity testing, per day, 8-14 drug class(es), including metabolite(s) if performed
G0482	Addition	$123.97	Drug tests), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)); qualitative or quantitative, all sources, includes specimen validity testing, per day, 15-21 drug class(es), including metabolite(s) if performed
G0483	Addition	$160.71	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to GC/MS (any type, single or tandem) and LC/MS (any type, single or tandem and excluding immunoassays (e.g., IA, EIA, ELISA, EMIT, FPIA) and enzymatic methods (e.g., alcohol dehydrogenase)); qualitative or quantitative, all sources, includes specimen validity testing, per day, 22 or more drug class(es), including metabolite(s) if performed
G6030	Delete		
G6031	Delete		
G6032	Delete		
G6034	Delete		
G6035	Delete		
G6036	Delete		
G6037	Delete		
G6038	Delete		
G6039	Delete		
G6040	Delete		
G6041	Delete		
G6042	Delete		
G6043	Delete		

Code	Change	Rate	Code Description (if applicable)
G6044	Delete		5
G6045	Delete		
G6046	Delete		
G6047	Delete		
G6048	Delete		
G6049	Delete		
G6050	Delete		
G6051	Delete		
G6052	Delete		
G6053	Delete		
G6054	Delete		
G6055	Delete		
G6056	Delete		
G6057	Delete		
G6058	Delete		